Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Empagliflozin and Dapagliflozin in Patients Hospitalized for Acute Decompensated Heart Failure (EMPATHY) - a Phase III Trial.

NCT05776043 is registered in ClinicalTrials.gov with Medical University of Warsaw as lead sponsor.

NCT NCT05776043
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05776043 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Empagliflozin and Dapagliflozin in Patients Hospitalized for Acute Decompensated Heart Failure (EMPATHY) - a Phase III Trial.
Lead sponsor
Medical University of Warsaw
Phase
Phase 3
Overall status
Unknown status
Start date
March 15, 2022
Completion date
December 31, 2025
Enrollment
1,364 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute decompensated heart failure